Farooq Fawad, Imran Nida, Abbas Mahwish
Department of Cardiology, National Institute of Cardiovascular Diseases, Karachi, Pakistan.
National Institute of Cardiovascular Diseases (NICVD), Karachi-Pakistan.
J Pak Med Assoc. 2021 Jan;71(1(A)):86-89. doi: 10.47391/JPMA.638.
To determine the effect of Ivabradine in lowering heart rate and quality of life in chronic heart failure patients.
The observational study was conducted in the out-patient department of the National Institute of Cardiovascular Disease, Karachi, from December 2016 to June 2017, and comprised chronic heart failure patients aged 30-70 years who were on 5mg Ivabradine for 8-weeks. Heart rate was evaluated through electrocardiogram, and health-related quality of life was measured using the validated questionnaire. Baseline demographics and clinical characteristics were recorded, with follow-ups at week-4 and week-8. Safety and tolerability were assessed by adverse drug reactions monitoring. Data was analysed using SPSS 21.
Of the 50 patients, 34(68%) were males. The overall mean age was 54.8±9.17 years. Baseline mean heart rate significantly reduced at first and second follow-up visit (p< 0.001). Mobility problems declined significantly as well (p<0.05). Health-related quality of life significantly improved on follow-up visits (p<0.001).
There was significant control of heart rate in chronic heart failure patients with improvement in all parameters of quality of life.
确定伊伐布雷定对慢性心力衰竭患者降低心率及生活质量的影响。
2016年12月至2017年6月在卡拉奇国家心血管病研究所门诊部进行了一项观察性研究,纳入年龄在30 - 70岁、服用5毫克伊伐布雷定8周的慢性心力衰竭患者。通过心电图评估心率,并使用经过验证的问卷测量与健康相关的生活质量。记录基线人口统计学和临床特征,并在第4周和第8周进行随访。通过监测药物不良反应评估安全性和耐受性。使用SPSS 21对数据进行分析。
50例患者中,34例(68%)为男性。总体平均年龄为54.8±9.17岁。在第一次和第二次随访时,基线平均心率显著降低(p<0.001)。活动问题也显著减少(p<0.05)。随访时与健康相关的生活质量显著改善(p<0.001)。
慢性心力衰竭患者的心率得到显著控制,生活质量的所有参数均有所改善。